| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J S Barton, S Cullen, P C Hindmarsh, C G Brook, M A Preec. Growth hormone treatment in idiopathic short stature: a preliminary analysis of cardiovascular effects. Acta paediatrica (Oslo, Norway : 1992). Supplement. vol 383. 1993-01-14. PMID:1305808. |
abnormalities in the renin-angiotensin-aldosterone (raa) system have been reported in acromegaly and in normal adults treated with recombinant human gh. |
1993-01-14 |
2023-08-11 |
human |
| V J Coulson, J A Wass, A F Abdulla, A M Cotterill, J M Holl. Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth regulation. vol 1. issue 3. 1993-01-14. PMID:1726836. |
hypersecretion of growth hormone (gh) is the principal feature of acromegaly and is accompanied by an excess of igf-i production which mediates some of the actions of gh. |
1993-01-14 |
2023-08-11 |
Not clear |
| A Giustina, M Schettino, C Bodini, M Doga, M Licini, G Giustin. Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. Metabolism: clinical and experimental. vol 41. issue 12. 1993-01-13. PMID:1281259. |
in acromegaly, circulating gh levels are increased and the gh response to ghrh may be exaggerated. |
1993-01-13 |
2023-08-11 |
human |
| A Giustina, M Schettino, C Bodini, M Doga, M Licini, G Giustin. Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. Metabolism: clinical and experimental. vol 41. issue 12. 1993-01-13. PMID:1281259. |
galanin has been recently shown to decrease circulating gh levels in acromegaly. |
1993-01-13 |
2023-08-11 |
human |
| N Hizuka, K Takano, K Asakawa, I Sukegawa, I Fukuda, H Demura, M Iwashita, T Adachi, K Shizum. Measurement of free form of insulin-like growth factor I in human plasma. Growth regulation. vol 1. issue 2. 1993-01-13. PMID:1668800. |
the figf-i values in normal adults, patients with acromegaly, and patients with growth hormone (gh)-deficiency were 2.4 +/- 0.1, 13.8 +/- 1.6, and 1.1 +/- 0.1 ng/ml, respectively. |
1993-01-13 |
2023-08-11 |
human |
| H Watanobe, K Takeb. A further study on the stimulatory effect of peptide histidine methionine on growth hormone secretion in acromegaly: a dose-related study and a comparison with vasoactive intestinal peptide. Neuropeptides. vol 23. issue 2. 1993-01-06. PMID:1333573. |
we examined whether the gh-releasing effect of peptide histidine methionine (phm) in acromegaly may be mediated by activation of pituitary receptors for vasoactive intestinal peptide (vip), which is structurally similar to but more powerful than phm in stimulating gh secretion in acromegaly. |
1993-01-06 |
2023-08-11 |
Not clear |
| H Watanobe, K Takeb. A further study on the stimulatory effect of peptide histidine methionine on growth hormone secretion in acromegaly: a dose-related study and a comparison with vasoactive intestinal peptide. Neuropeptides. vol 23. issue 2. 1993-01-06. PMID:1333573. |
bolus to 11 patients with active acromegaly, and plasma gh levels were measured before and at intervals up to 120 min after the injection. |
1993-01-06 |
2023-08-11 |
Not clear |
| T C Chang, C C Chang, K S Tsai, T S Huang, W Y Tsai, M H Lin, F W Che. Clinical experience of octreotide in the treatment of acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 91. issue 6. 1992-12-18. PMID:1358345. |
in conclusion, octreotide is effective in the treatment of acromegaly; however, it is better used in patients who have serum gh levels < 20 mu/l, or after a trans-sphenoidal adenomectomy, and may be combined with bromocriptine to treat the patient. |
1992-12-18 |
2023-08-11 |
Not clear |
| M Riedel, T Günther, A von zur Mühlen, G Braban. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin? Clinical endocrinology. vol 37. issue 3. 1992-12-09. PMID:1358484. |
the pulsatile gh secretion in acromegaly: hypothalamic or pituitary origin? |
1992-12-09 |
2023-08-11 |
Not clear |
| M Riedel, T Günther, A von zur Mühlen, G Braban. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin? Clinical endocrinology. vol 37. issue 3. 1992-12-09. PMID:1358484. |
we studied the effects of different modes of octreotide therapy on the pulsatile pattern of gh release in an attempt to define better its regulation by growth hormone-releasing hormone (ghrh) and somatostatin and its effects on igf-i plasma levels in acromegaly. |
1992-12-09 |
2023-08-11 |
Not clear |
| A J van der Lely, A G Harris, S W Lambert. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clinical endocrinology. vol 37. issue 2. 1992-11-10. PMID:1395069. |
we investigated the relationship between age, sex, pituitary tumour volume, serum gh, prl and igf-i levels with the responsiveness of gh to trh, bromocriptine and octreotide in patients with acromegaly. |
1992-11-10 |
2023-08-11 |
Not clear |
| A A Bulatov, I S Komolov, N B Smirnova, Iu K Trunin, S Iu Serpukhovitin, L K Dzeranova, E I Marova, I I Dedo. [Regulation of hormone secretion in primary cell cultures of human somatotropinomas]. Biulleten' eksperimental'noi biologii i meditsiny. vol 113. issue 4. 1992-11-06. PMID:1356509. |
the effects of somatostatin and thyroliberin (thyrotropin-releasing hormone; trh) on growth hormone (gh) and prolactin (prl) secretion were studied in short-term (0.5-3h) or long-term (21-24h) incubations using monolayer cell cultures of somatotropin obtained from surgical material of patients with acromegaly. |
1992-11-06 |
2023-08-11 |
human |
| C M Villabona, J Soler, N Virgili, J M Gómez, E Montaña, M A Navarr. Growth hormone response to thyrotropin-releasing hormone in acromegalic patients: reproducibility and dose-response study. Hormone research. vol 37. issue 1-2. 1992-11-06. PMID:1398470. |
the aim of the study was to analyze 14 consecutive patients with active acromegaly who had not undergone any therapy, the dose response of growth hormone (gh) to thyrotropin-releasing hormone (trh), the existence of reproducibility of such response as well as to rule out the possibility of spontaneous fluctuations of gh which would mimic this response. |
1992-11-06 |
2023-08-11 |
Not clear |
| A L Hulting, E Theodorsson, S Werne. Thyrotropin-releasing hormone increases serum levels of growth hormone-releasing hormone and growth hormone in patients with acromegaly. Journal of internal medicine. vol 232. issue 3. 1992-10-29. PMID:1402619. |
the effect of intravenous injection of thyrotropin-releasing hormone (trh) on the plasma concentrations of growth hormone (gh) and growth hormone-releasing hormone (ghrh) was studied in seven patients with acromegaly and in five control subjects. |
1992-10-29 |
2023-08-11 |
human |
| A L Hulting, E Theodorsson, S Werne. Thyrotropin-releasing hormone increases serum levels of growth hormone-releasing hormone and growth hormone in patients with acromegaly. Journal of internal medicine. vol 232. issue 3. 1992-10-29. PMID:1402619. |
a 'paradoxical' increase in plasma gh in response to trh was observed in four of the seven patients with acromegaly. |
1992-10-29 |
2023-08-11 |
human |
| A L Hulting, E Theodorsson, S Werne. Thyrotropin-releasing hormone increases serum levels of growth hormone-releasing hormone and growth hormone in patients with acromegaly. Journal of internal medicine. vol 232. issue 3. 1992-10-29. PMID:1402619. |
no trh-induced increase in ghrh levels was observed in the other three patients with acromegaly who did not display an increase in gh in response to trh. |
1992-10-29 |
2023-08-11 |
human |
| A L Hulting, E Theodorsson, S Werne. Thyrotropin-releasing hormone increases serum levels of growth hormone-releasing hormone and growth hormone in patients with acromegaly. Journal of internal medicine. vol 232. issue 3. 1992-10-29. PMID:1402619. |
the present results imply that ghrh may be involved in the plasma gh response to trh in patients with acromegaly. |
1992-10-29 |
2023-08-11 |
human |
| S J Brockmeier, M Buchfelder, E F Adams, W Schott, R Fahlbusc. Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 24. issue 8. 1992-10-22. PMID:1526628. |
the authors conclude that even the finding of repetitive 'normal' (less than or equal to 5 ng/ml) serum gh levels does not exclude active acromegaly and when the clinical diagnosis of acromegaly is suspected, dynamic endocrine testing may reveal abnormal secretion patterns of gh in these cases. |
1992-10-22 |
2023-08-11 |
Not clear |
| R Cohen, P Chanson, E Bruckert, J Timsit, A Legrand, A G Harris, P J Guillausseau, A Warnet, J Lubetzk. Effects of octreotide on lipid metabolism in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 24. issue 8. 1992-10-22. PMID:1526629. |
the somatostatin analog, octreotide (sandostatin), widely used in the treatment of acromegaly, is able to produce a decrease in levels of growth hormone (gh), insulin, and insulin-like growth factor 1 (igf1). |
1992-10-22 |
2023-08-11 |
Not clear |
| P J Ho, R D Friberg, A Barka. Fasting-induced changes in thyroid hormone economy in normal and acromegalic subjects. Thyroid : official journal of the American Thyroid Association. vol 2. issue 1. 1992-10-16. PMID:1525564. |
to study whether high growth hormone (gh) milieu may counteract fasting-induced changes in thyroid hormone economy, we measured basal and trh-stimulated tsh concentrations as well as thyroxine (total, tt4 and free, ft4), total triiodothyronine (tt3) and total reverse t3 (trt3) before and after a 6-day fast in 6 healthy men and in 8 patients with acromegaly. |
1992-10-16 |
2023-08-11 |
human |